The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
Abstract
CONTEXT: Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality. OBJECTIVE: To evaluate the effect of screening for ovarian cancer on mortality in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial of 78,216 women aged 55 to 74 years assigned to undergo either annual screening (n = 39,105) or usual care (n = 39,111) at 10 screening centers across the United States between November 1993 and July 2001. Intervention The intervention group was offered annual screening with CA-125 for 6 years and transvaginal ultrasound for 4 years. Participants and their health care practitioners received the screening test results and managed evaluation of abnormal results. The usual care group was not offered annual screening with CA-125 for 6 years or transvaginal ultrasound but received their usual medical care. Participants were followed up for a maximum of 13 years (median [range], 12.4 years [10.9-13.0 years]) for cancer diagnoses and death until February 28, 2010. MAIN OUTCOME MEASURES: Mortality from ovarian cancer, including primary peritoneal and fallopian tube cancers. Secondary outcomes included ovarian cancer incidence and complications associated with screening examinations and diagnostic procedures. RESULTS: Ovarian cancer was diagnosed in 212 women (5.7 per 10,000 person-years) in the intervention group and 176 (4.7 per 10,000 person-years) in the usual care group (rate ratio [RR], 1.21; 95% confidence interval [CI], 0.99-1.48). There were 118 deaths caused by ovarian cancer (3.1 per 10,000 person-years) in the intervention group and 100 deaths (2.6 per 10,000 person-years) in the usual care group (mortality RR, 1.18; 95% CI, 0.82-1.71). Of 3285 women with false-positive results, 1080 underwent surgical follow-up; of whom, 163 women experienced at least 1 serious complication (15%). There were 2924 deaths due to other causes (excluding ovarian, colorectal, and lung cancer) (76.6 per 10,000 person-years) in the intervention group and 2914 deaths (76.2 per 10,000 person-years) in the usual care group (RR, 1.01; 95% CI, 0.96-1.06). CONCLUSIONS: Among women in the general US population, simultaneous screening with CA-125 and transvaginal ultrasound compared with usual care did not reduce ovarian cancer mortality. Diagnostic evaluation following a false-positive screening test result was associated with complications. Trial Registration clinicaltrials.gov Identifier: NCT00002540.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations
Elmore, J. G., Barton, M. B., Moceri, V. M., Polk, S., Arena, P. J., & Fletcher, S. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381601 · Cited by 1,053
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Self-citationMenon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Screening for ovarian cancer: a pilot randomised controlled trial
Jacobs, I. J., Skates, S. J., MacDonald, N., Menon, U., Rosenthal, A. N., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10261-1 · Cited by 560
Gohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Buys, S. S., Partridge, E., Greene, M. H., Prorok, P. C., Reding, D., Riley, T. L., Hartge, P., Fagerstrom, R. M., Ragard, L. R., Chia, D., et al. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.05.005 · Cited by 346
Self-citationA randomized study of screening for ovarian cancer: a multicenter study in Japan
KOBAYASHI, H., YAMADA, Y., SADO, T., SAKATA, M., YOSHIDA, S., KAWAGUCHI, R., KANAYAMA, S., SHIGETOMI, H., HARUTA, S., TSUJI, Y., et al. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01035.x · Cited by 276
Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J.-L., Church, T. R., Kessel, B., Johnson, C. C., Weissfeld, J. L., Isaacs, C., et al. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31819cda77 · Cited by 258
Self-citation
Cited by
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Lin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Chornokur, G., Lin, H.-Y., Tyrer, J. P., Lawrenson, K., Dennis, J., Amankwah, E. K., Qu, X., Tsai, Y.-Y., Jim, H. S. L., Chen, Z., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128106 · Cited by 902
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Menon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00731-5 · Cited by 730
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., Brawley, O. W., & Wender, R. C. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21392 · Cited by 719
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., & Wender, R. C. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21557 · Cited by 701
CA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., Brawley, O. W., & Wender, R. C. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21446 · Cited by 571
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., Setiawan, V. W., Visvanathan, K., Weiderpass, E., Adami, H.-O., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.8178 · Cited by 514
“Screening for ovarian cancer did not reduce mortality in two large screening trials.(2,3) An understanding of the etiologic heterogeneity of ovarian cancer is critical for development of new prevention strategies.”
BackgroundSelf-citationCancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Van Calster, B., Van Hoorde, K., Valentin, L., Testa, A. C., Fischerova, D., Van Holsbeke, C., Savelli, L., Franchi, D., Epstein, E., Kaijser, J., et al. (2014) · BMJ · doi:10.1136/bmj.g5920 · Cited by 510
Smith, R. A., Manassaram-Baptiste, D., Brooks, D., Cokkinides, V., Doroshenk, M., Saslow, D., Wender, R. C., & Brawley, O. W. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21212 · Cited by 478
Smith, R. A., Brooks, D., Cokkinides, V., Saslow, D., & Brawley, O. W. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21174 · Cited by 422
Maron, B. J., Friedman, R. A., Kligfield, P., Levine, B. D., Viskin, S., Chaitman, B. R., Okin, P. M., Saul, J. P., Salberg, L., Van Hare, G. F., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000025 · Cited by 390
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188503 · Cited by 384
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
Kurman, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt463 · Cited by 336
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12614 · Cited by 327
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Kurnit, K. C., Fleming, G. F., & Lengyel, E. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004173 · Cited by 322
Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(12)60025-3 · Cited by 322
Nelson, H. D., Pappas, M., Zakher, B., Mitchell, J. P., Okinaka-Hu, L., & Fu, R. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1684 · Cited by 319
Endometriosis and cancer: a systematic review and meta-analysis
Kvaskoff, M., Mahamat-Saleh, Y., Farland, L. V., Shigesi, N., Terry, K. L., Harris, H. R., Roman, H., Becker, C. M., As-Sanie, S., Zondervan, K. T., et al. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa045 · Cited by 303
Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9021 · Cited by 303
Parkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 297
Thomassin-Naggara, I., Poncelet, E., Jalaguier-Coudray, A., Guerra, A., Fournier, L. S., Stojanovic, S., Millet, I., Bharwani, N., Juhan, V., Cunha, T. M., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.19896 · Cited by 296
Cancer Screening and Early Detection in the 21st Century
Loud, J. T., & Murphy, J. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.02.002 · Cited by 289
McAlpine, J. N., Hanley, G. E., Woo, M. M. M., Tone, A. A., Rozenberg, N., Swenerton, K. D., Gilks, C. B., Finlayson, S. J., Huntsman, D. G., & Miller, D. M. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.01.003 · Cited by 286
The role of the fallopian tube in the origin of ovarian cancer
Erickson, B. K., Conner, M. G., & Landen, C. N. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.04.019 · Cited by 286
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2018) · JAMA · doi:10.1001/jama.2017.21926 · Cited by 283
Ovarian Cancer Prevention and Screening
Menon, U., Karpinskyj, C., & Gentry-Maharaj, A. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002580 · Cited by 279
Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
Duffy, M. J. (2013) · Medical Principles and Practice · doi:10.1159/000338393 · Cited by 278
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Havrilesky, L. J., Moorman, P. G., Lowery, W. J., Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318291c235 · Cited by 258
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer
Sölétormos, G., Duffy, M. J., Hassan, S. O. A., Verheijen, R. H. M., Tholander, B., Bast, R. C., Gaarenstroom, K. N., Sturgeon, C. M., Bonfrer, J. M., Petersen, P. H., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000586 · Cited by 255
The Origin of Ovarian Cancer Species and Precancerous Landscape
Shih, I.-M., Wang, Y., & Wang, T.-L. (2021) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.09.006 · Cited by 255
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Rojas, V., Hirshfield, K., Ganesan, S., & Rodriguez-Rodriguez, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122113 · Cited by 254
Trabert, B., Ness, R. B., Lo-Ciganic, W.-H., Murphy, M. A., Goode, E. L., Poole, E. M., Brinton, L. A., Webb, P. M., Nagle, C. M., Jordan, S. J., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt431 · Cited by 243
Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., Wietek, N., Alsaadi, A., Carrami, E. M., Hu, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0637-x · Cited by 218
Three myths about risk thresholds for prediction models
on behalf of the Topic Group ‘Evaluating diagnostic tests and prediction models’ of the STRATOS initiative, Wynants, L., van Smeden, M., McLernon, D. J., Timmerman, D., Steyerberg, E. W., & Van Calster, B. (2019) · BMC Medicine · doi:10.1186/s12916-019-1425-3 · Cited by 213
Pinsky, P. F., Yu, K., Kramer, B. S., Black, A., Buys, S. S., Partridge, E., Gohagan, J., Berg, C. D., & Prorok, P. C. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.334 · Cited by 191
Self-citationPARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Dziadkowiec, K. N., Gąsiorowska, E., Nowak-Markwitz, E., & Jankowska, A. (2016) · Menopausal Review · doi:10.5114/pm.2016.65667 · Cited by 191
Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant
Williams, R. M., Lee, C., Galassi, T. V., Harvey, J. D., Leicher, R., Sirenko, M., Dorso, M. A., Shah, J., Olvera, N., Dao, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aaq1090 · Cited by 183
Christiansen, F., Epstein, E. L., Smedberg, E., Åkerlund, M., Smith, K., & Epstein, E. (2021) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.23530 · Cited by 142
Spin and Boasting in Research Articles
Cummings, P., & Rivara, F. P. (2012) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2012.1461 · Cited by 19
Ultrasound Screening for Ovarian Cancer: Are We There Yet?
Robertson, S. E., & Peipert, J. F. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002962 · Cited by 6
Abdel-Razeq, H., & Mansour, R. (2026) · World Journal of Oncology · doi:10.14740/wjon2692
Metadata
- Authors
- Buys, S. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-06-08
- Volume
- 305
- Issue
- 22
- Pages
- 2295
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2128104740
- Cited by
- 1,323
- References
- 22
- FWCI
- 104.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.